Foghorn Therapeutics(FHTX)
Focus: Foghorn Therapeutics is a public Cambridge-based biotech focused on cancer drug discovery through protein degradation mechanisms. The company is early-stage with all programs in Phase 1 clinical development and minimal commercial revenue.
Profile data last refreshed 16m ago · AI intelligence enriched 2mo ago
Funding Stage
PUBLIC
Open Jobs
0
About Foghorn Therapeutics
AI assessmentNot HiringNo open roles listed right now. Follow Foghorn Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Foghorn Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthStrong
Pipeline
Early-stage
4 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$23M
Pipeline & Clinical Trials
FHD-609
Advanced Synovial SarcomaClinical Trials (1)
NCT04965753FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors
Phase 1Help build intelligence for Foghorn Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.